SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Moxifloxacin Liquid Formulation

SECTION 1. IDENTIFICATION

Product name: Moxifloxacin Liquid Formulation

Manufacturer or supplier’s details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Reproductive toxicity: Category 2

GHS label elements
Hazard pictograms: [Image]
Signal Word: Warning
Hazard Statements: H361d Suspected of damaging the unborn child.
Precautionary Statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Moxifloxacin Liquid Formulation

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin HCL</td>
<td>186826-86-8</td>
<td>&gt;= 0.1 - &lt;= 0.2</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during firefighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : No hazardous combustion products are known

Specific extinguishing methods : Use extinguishing measures that are appropriate to local cir-
SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Avoid inhalation of vapor or mist.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin HCL</td>
<td>186826-86-8</td>
<td>TWA</td>
<td>1000 µg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection Material: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Moxifloxacin Liquid Formulation

 SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

   Appearance : liquid
   Color : yellow
   Odor : odorless
   Odor Threshold : No data available
   pH : 4.1 - 4.6
   Melting point/freezing point : No data available
   Initial boiling point and boiling range : No data available
   Flash point : No data available
   Evaporation rate : No data available
   Flammability (solid, gas) : Not applicable
   Flammability (liquids) : No data available
   Upper explosion limit / Upper flammability limit : No data available
   Lower explosion limit / Lower flammability limit : No data available
   Vapor pressure : No data available
   Relative vapor density : No data available
   Relative density : No data available
   Density : 1.0044 g/cm³ (68 °F / 20 °C)
   Solubility(ies)
      Water solubility : slightly soluble
   Partition coefficient: n-octanol/water : No data available
   Autoignition temperature : No data available
   Decomposition temperature : No data available
   Viscosity
      Viscosity, kinematic : No data available
   Explosive properties : Not explosive

use of administrative controls.
Oxidizing properties: The substance or mixture is not classified as oxidizing.

Molecular weight: No data available

Particle size: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Moxifloxacin HCL:
Acute oral toxicity:
LD50 (Rat): 1,320 mg/kg
LD50 (Mouse): > 435 mg/kg
LD50 (Monkey): 1,500 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Moxifloxacin HCL:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:

Moxifloxacin HCL:

Species: Rabbit
Result: Moderate eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: positive
- Test Type: Chromosome aberration test in vitro
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
- Test Type: in vitro micronucleus test
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Application Route: Oral
  Result: negative

Carcinogenicity
Not classified based on available information.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.
Components:

Moxifloxacin HCL:

Effects on fertility:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Oral
- Fertility: LOAEL: 500 mg/kg body weight
- Result: Effects on fertility.

Effects on fetal development:
- Test Type: Embryo-fetal development
- Species: Monkey
- Application Route: Oral
- Developmental Toxicity: NOAEL: 10 mg/kg body weight
- Result: negative

Test Type: Embryo-fetal development
- Species: Rabbit
- Application Route: Intravenous injection
- Developmental Toxicity: LOAEL: 20 mg/kg body weight
- Symptoms: Skeletal malformations.

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Moxifloxacin HCL:

Target Organs:
- Liver

Assessment:
- May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:

Species:
- Rat
- LOAEL: 100 mg/kg
- Application Route: Oral
- Exposure time: 4 Weeks

Species:
- Rat
- NOAEL: 100 mg/kg
- Application Route: Oral
- Exposure time: 13 Weeks
- Target Organs: Liver
- Symptoms: Liver disorders
**SAFETY DATA SHEET**

**Moxifloxacin Liquid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10</td>
<td>09/30/2023</td>
<td>1731714-00014</td>
<td>04/26/2023</td>
<td>06/05/2017</td>
</tr>
</tbody>
</table>

- **Species**: Rat
- **NOAEL**: 20 mg/kg
- **Application Route**: Oral
- **Exposure time**: 6 Months
- **Target Organs**: Liver
- **Symptoms**: Liver disorders

- **Species**: Monkey
- **NOAEL**: 50 mg/kg
- **Application Route**: Oral
- **Exposure time**: 4 Weeks
- **Symptoms**: No adverse effects.

- **Species**: Monkey
- **NOAEL**: 15 mg/kg
- **Application Route**: Oral
- **Exposure time**: 13 Weeks
- **Target Organs**: Gastrointestinal tract
- **Symptoms**: Vomiting

- **Species**: Monkey
- **Application Route**: Oral
- **Exposure time**: 26 Weeks
- **Target Organs**: Liver
- **Symptoms**: Liver disorders

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

**Moxifloxacin HCL:**

- **Ingestion**: Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

No data available

**Persistence and degradability**

No data available

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Other adverse effects**

No data available
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Moxifloxacin Liquid Formulation

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste
handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
49 CFR
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations
Pennsylvania Right To Know
Water 7732-18-5
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Moxifloxacin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10</td>
<td>09/30/2023</td>
<td>1731714-00014</td>
<td>04/26/2023</td>
<td>06/05/2017</td>
</tr>
</tbody>
</table>

The ingredients of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

### SECTION 16. OTHER INFORMATION

**Further information**

<table>
<thead>
<tr>
<th>NFPA 704:</th>
<th>HMIS® IV:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability</td>
<td>HEALTH</td>
</tr>
<tr>
<td>Health</td>
<td>FLAMMABILITY</td>
</tr>
<tr>
<td>Instability</td>
<td>PHYSICAL HAZARD</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "+" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Moxifloxacin Liquid Formulation

Revision Date: 09/30/2023
SDS Number: 1731714-00014
Date of last issue: 04/26/2023
Date of first issue: 06/05/2017

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8